Filter by:
Muscular Dystrophy
May 2021
Muscle & Nerve, March 8, 2021
Scientific Posters and Presentations
Use the search tool to explore publications, posters and presentations and take a deep dive into our leadership in serious cardiovascular diseases.
In July 2026, Servier acquired Edgewise’s muscular dystrophy business, including sevasemten. To support patients, researchers, and healthcare professionals, sevasemten-related posters, presentations, and publications will remain accessible on this page for a limited time.
We are advancing novel precision therapeutics for serious cardiovascular disease.
2026 © Copyright. Edgewise Therapeutics. All Rights Reserved.